OA11572A - PyrroloÄ2,3-düpyrimidine compounds. - Google Patents

PyrroloÄ2,3-düpyrimidine compounds. Download PDF

Info

Publication number: OA11572A
Authority: OA; OAPI
Prior art keywords: alkyl; pyrrolo; methyl; pyrimidin; amino
Prior art date: 1998-06-19

Application number

OA1200000349A

Other languages

English (en)

Inventor

Todd Andrew Blumenkopf

Matthew Frank Brown

Paul Steven Changelian

Mark Edward Flanagan

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1999-06-14

Publication date

2004-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26781018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-14 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-07-01 Publication of OA11572A publication Critical patent/OA11572A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 102
208000006673 asthma Diseases 0.000 claims abstract description 11
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 11
206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 10
206010028980 Neoplasm Diseases 0.000 claims abstract description 10
201000004681 Psoriasis Diseases 0.000 claims abstract description 10
208000024799 Thyroid disease Diseases 0.000 claims abstract description 10
201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 10
230000001363 autoimmune Effects 0.000 claims abstract description 10
201000011510 cancer Diseases 0.000 claims abstract description 10
208000032839 leukemia Diseases 0.000 claims abstract description 10
206010025135 lupus erythematosus Diseases 0.000 claims abstract description 10
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
208000011231 Crohn disease Diseases 0.000 claims abstract description 9
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 9
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 9
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 9
210000000056 organ Anatomy 0.000 claims abstract description 9
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
125000000217 alkyl group Chemical group 0.000 claims description 176
-1 hydroxy, amino Chemical group 0.000 claims description 76
108010019421 Janus Kinase 3 Proteins 0.000 claims description 30
102000006500 Janus Kinase 3 Human genes 0.000 claims description 30
125000003545 alkoxy group Chemical group 0.000 claims description 29
125000001072 heteroaryl group Chemical group 0.000 claims description 27
125000000041 C6-C10 aryl group Chemical group 0.000 claims description 24
229910052739 hydrogen Inorganic materials 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 23
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
125000002252 acyl group Chemical group 0.000 claims description 21
125000004442 acylamino group Chemical group 0.000 claims description 20
125000000753 cycloalkyl group Chemical group 0.000 claims description 20
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 19
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 18
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 17
125000003282 alkyl amino group Chemical group 0.000 claims description 17
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
208000035475 disorder Diseases 0.000 claims description 13
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 13
125000004423 acyloxy group Chemical group 0.000 claims description 12
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 11
150000002431 hydrogen Chemical class 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 8
206010052779 Transplant rejections Diseases 0.000 claims description 8
125000000304 alkynyl group Chemical group 0.000 claims description 8
229910052805 deuterium Inorganic materials 0.000 claims description 8
206010003645 Atopy Diseases 0.000 claims description 7
201000004624 Dermatitis Diseases 0.000 claims description 7
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 6
125000003342 alkenyl group Chemical group 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 6
229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
239000002260 anti-inflammatory agent Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
210000000987 immune system Anatomy 0.000 claims description 4
125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
108091000080 Phosphotransferase Proteins 0.000 claims description 2
102000020233 phosphotransferase Human genes 0.000 claims description 2
102200031660 rs730880032 Human genes 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 4
125000001475 halogen functional group Chemical group 0.000 claims 3
QJLJAWHLBAUMAA-UHFFFAOYSA-N 2-[1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)azetidin-3-yl]propan-2-ol Chemical compound C1C(C(C)(O)C)CN1C1=NC=NC2=C1C=CN2 QJLJAWHLBAUMAA-UHFFFAOYSA-N 0.000 claims 1
ZRJHSCQQVJJAFE-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]propan-2-ol Chemical compound CC1CCC(C(C)(C)O)CC1N(C)C1=NC=NC2=C1C=CN2 ZRJHSCQQVJJAFE-UHFFFAOYSA-N 0.000 claims 1
FACYDAGCXBRLET-UHFFFAOYSA-N 2-[4-methyl-5-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohex-3-en-1-yl]propan-2-ol Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C1CC(C(C)(C)O)CC=C1C FACYDAGCXBRLET-UHFFFAOYSA-N 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
ZHMNGSTXFYRERK-UHFFFAOYSA-N n-(2-ethyl-4-prop-1-en-2-ylcyclopentyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CCC1CC(C(C)=C)CC1N(C)C1=NC=NC2=C1C=CN2 ZHMNGSTXFYRERK-UHFFFAOYSA-N 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 abstract description 5
229940125721 immunosuppressive agent Drugs 0.000 abstract description 2
239000003112 inhibitor Substances 0.000 abstract description 2
238000002560 therapeutic procedure Methods 0.000 abstract description 2
206010012438 Dermatitis atopic Diseases 0.000 abstract 1
102000015617 Janus Kinases Human genes 0.000 abstract 1
108010024121 Janus Kinases Proteins 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
201000008937 atopic dermatitis Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
238000000034 method Methods 0.000 description 63
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
239000000203 mixture Substances 0.000 description 40
239000000243 solution Substances 0.000 description 38
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
238000006243 chemical reaction Methods 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
238000002844 melting Methods 0.000 description 22
230000008018 melting Effects 0.000 description 22
150000003839 salts Chemical class 0.000 description 22
125000003118 aryl group Chemical group 0.000 description 21
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
239000011541 reaction mixture Substances 0.000 description 18
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 17
239000002585 base Substances 0.000 description 17
239000000047 product Substances 0.000 description 17
229940093499 ethyl acetate Drugs 0.000 description 15
235000019439 ethyl acetate Nutrition 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
239000007787 solid Substances 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
125000005843 halogen group Chemical group 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
239000002253 acid Substances 0.000 description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
108010036949 Cyclosporine Proteins 0.000 description 8
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
125000004093 cyano group Chemical group *C#N 0.000 description 8
238000010992 reflux Methods 0.000 description 8
125000004414 alkyl thio group Chemical group 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
238000001816 cooling Methods 0.000 description 7
239000002904 solvent Substances 0.000 description 7
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 6
125000004391 aryl sulfonyl group Chemical group 0.000 description 6
125000005110 aryl thio group Chemical group 0.000 description 6
239000012267 brine Substances 0.000 description 6
150000001768 cations Chemical class 0.000 description 6
239000012043 crude product Substances 0.000 description 6
LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 5
102000004388 Interleukin-4 Human genes 0.000 description 5
108090000978 Interleukin-4 Proteins 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
125000005135 aryl sulfinyl group Chemical group 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
125000004193 piperazinyl group Chemical group 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
229910000104 sodium hydride Inorganic materials 0.000 description 5
125000006528 (C2-C6) alkyl group Chemical group 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Natural products NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000003513 alkali Substances 0.000 description 4
125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
229930105110 Cyclosporin A Natural products 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
125000004656 alkyl sulfonylamino group Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
229940077388 benzenesulfonate Drugs 0.000 description 3
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
229940043279 diisopropylamine Drugs 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
238000005227 gel permeation chromatography Methods 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
229960003444 immunosuppressant agent Drugs 0.000 description 3
230000001861 immunosuppressant effect Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
125000005936 piperidyl group Chemical group 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
235000011118 potassium hydroxide Nutrition 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
229940063122 sandimmune Drugs 0.000 description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011592 zinc chloride Substances 0.000 description 3
235000005074 zinc chloride Nutrition 0.000 description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
HFHPBMVMXFZJNO-UHFFFAOYSA-N 1-(cyclohexylamino)propan-2-ol Chemical compound CC(O)CNC1CCCCC1 HFHPBMVMXFZJNO-UHFFFAOYSA-N 0.000 description 2
MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 2
ZYUZIQCTDGCTPB-UHFFFAOYSA-N 5-chloro-4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C=12C(Cl)=CNC2=NC=NC=1N1CCCCC1 ZYUZIQCTDGCTPB-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
229960001040 ammonium chloride Drugs 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000004657 aryl sulfonyl amino group Chemical group 0.000 description 2
229940092117 atgam Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
229940073608 benzyl chloride Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229940107810 cellcept Drugs 0.000 description 2
238000000451 chemical ionisation Methods 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
CAOQEOHEZKVYOJ-UHFFFAOYSA-N cycloheptylmethanamine Chemical compound NCC1CCCCCC1 CAOQEOHEZKVYOJ-UHFFFAOYSA-N 0.000 description 2
MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
229960002806 daclizumab Drugs 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229910001882 dioxygen Inorganic materials 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
229960002706 gusperimus Drugs 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
229940073062 imuran Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
GHXZPUGJZVBLGC-UHFFFAOYSA-N iodoethene Chemical compound IC=C GHXZPUGJZVBLGC-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
229960000681 leflunomide Drugs 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
229940014456 mycophenolate Drugs 0.000 description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
BQHWWDQRAMXLHH-UHFFFAOYSA-N n,3-dimethylcyclohexan-1-amine Chemical compound CNC1CCCC(C)C1 BQHWWDQRAMXLHH-UHFFFAOYSA-N 0.000 description 2
IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 2
AUADWUSFXCHIQH-UHFFFAOYSA-N n-methyl-n-(3-methylcyclohexyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(C)CCCC1N(C)C1=NC=NC2=C1C=CN2 AUADWUSFXCHIQH-UHFFFAOYSA-N 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
229940063121 neoral Drugs 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
229960002702 piroxicam Drugs 0.000 description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960005205 prednisolone Drugs 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
230000011664 signaling Effects 0.000 description 2
229960002930 sirolimus Drugs 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
KNUKUWNSGVICSX-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)methanamine Chemical compound C1CC(CN)CCN1CC1=CC=CC=C1 KNUKUWNSGVICSX-UHFFFAOYSA-N 0.000 description 1
RCSSHZGQHHEHPZ-QMMMGPOBSA-N (1s)-n-methyl-1-phenylethanamine Chemical compound CN[C@@H](C)C1=CC=CC=C1 RCSSHZGQHHEHPZ-QMMMGPOBSA-N 0.000 description 1
FICBTSLUMJAISS-UHFFFAOYSA-N (2,2-dimethylcyclopentyl)methanamine Chemical compound CC1(C)CCCC1CN FICBTSLUMJAISS-UHFFFAOYSA-N 0.000 description 1
AOFFWPABORXTOB-UHFFFAOYSA-N (2,4-dimethylcyclohexyl)methanamine Chemical compound CC1CCC(CN)C(C)C1 AOFFWPABORXTOB-UHFFFAOYSA-N 0.000 description 1
SYYXPQCKXWLCCA-UHFFFAOYSA-N (2-ethylcyclohexyl)methanamine Chemical compound CCC1CCCCC1CN SYYXPQCKXWLCCA-UHFFFAOYSA-N 0.000 description 1
NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
UUFGEMRUTBNQMB-UHFFFAOYSA-N (4-ethylcyclohexyl)methanamine N-(4-ethylcyclohexyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CCC1CCC(CN)CC1.CCC1CCC(CC1)N(C)c1ncnc2[nH]ccc12 UUFGEMRUTBNQMB-UHFFFAOYSA-N 0.000 description 1
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
125000006529 (C3-C6) alkyl group Chemical group 0.000 description 1
125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 1
125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 description 1
QOENGHDDSYIDBH-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-ylmethanamine N-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CCCC2C(CN)CCCC21.C1CCC2CCCCC2C1N(C)C1=NC=NC2=C1C=CN2 QOENGHDDSYIDBH-UHFFFAOYSA-N 0.000 description 1
CFDAAXLRRSICLJ-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ylmethanamine N-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NCC1CCC2CCCCC2C1.CN(C1CCC2CCCCC2C1)c1ncnc2[nH]ccc12 CFDAAXLRRSICLJ-UHFFFAOYSA-N 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
CVHZCKZWBGOIFJ-UHFFFAOYSA-N 1-(cyclohexylamino)butan-2-ol Chemical compound CCC(O)CNC1CCCCC1 CVHZCKZWBGOIFJ-UHFFFAOYSA-N 0.000 description 1
VHBZLDYGXAEIDU-UHFFFAOYSA-N 1-(cyclohexylamino)ethanol Chemical compound CC(O)NC1CCCCC1 VHBZLDYGXAEIDU-UHFFFAOYSA-N 0.000 description 1
DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
GYKUYNGGIQAQIJ-UHFFFAOYSA-N 1-[cyclohexyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]butan-2-ol Chemical compound N=1C=NC=2NC=CC=2C=1N(CC(O)CC)C1CCCCC1 GYKUYNGGIQAQIJ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ABCFCYQKYRAHAX-UHFFFAOYSA-N 2-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-ylamino)ethanol Chemical compound C1CCCC2C(NCCO)CCCC21 ABCFCYQKYRAHAX-UHFFFAOYSA-N 0.000 description 1
IHBPOBAPIDMMRX-UHFFFAOYSA-N 2-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-yl)-1-aminoethanol Chemical compound C1CCCC2CC(CC(O)N)CCC21 IHBPOBAPIDMMRX-UHFFFAOYSA-N 0.000 description 1
LZZYNKWVOUYXAF-UHFFFAOYSA-N 2-[(2-ethyl-4-prop-1-en-2-ylcyclopentyl)-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethanol Chemical compound CCC1CC(C(C)=C)CC1N(CCO)C1=NC=NC2=C1C=CN2 LZZYNKWVOUYXAF-UHFFFAOYSA-N 0.000 description 1
NHYGTJJXGHCXNW-UHFFFAOYSA-N 2-[3-[2-hydroxyethyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-4-methylcyclohexyl]propan-2-ol Chemical compound CC1CCC(C(C)(C)O)CC1N(CCO)C1=NC=NC2=C1C=CN2 NHYGTJJXGHCXNW-UHFFFAOYSA-N 0.000 description 1
VIXNVCQFOFBIJM-UHFFFAOYSA-N 2-[3-ethyl-4-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclopentyl]propan-2-ol Chemical compound CCC1CC(C(C)(C)O)CC1N(C)C1=NC=NC2=C1C=CN2 VIXNVCQFOFBIJM-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
PRZWWSPGDMTXFY-UHFFFAOYSA-N 2-[pentan-3-yl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethanol Chemical compound CCC(CC)N(CCO)C1=NC=NC2=C1C=CN2 PRZWWSPGDMTXFY-UHFFFAOYSA-N 0.000 description 1
HJOQGBBHVRYTDX-UHFFFAOYSA-N 2-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=C2C=CNC2=N1 HJOQGBBHVRYTDX-UHFFFAOYSA-N 0.000 description 1
SONTVQKOIRDSEQ-UHFFFAOYSA-N 2-sulfinylpyrrolo[2,3-d]pyrimidine Chemical compound O=S=C1N=CC2=CC=NC2=N1 SONTVQKOIRDSEQ-UHFFFAOYSA-N 0.000 description 1
OXYJOLIHFRNKIB-UHFFFAOYSA-N 3-(cycloheptylamino)propan-1-ol Chemical compound OCCCNC1CCCCCC1 OXYJOLIHFRNKIB-UHFFFAOYSA-N 0.000 description 1
YDVGXVAWWFKAKA-UHFFFAOYSA-N 3-(cyclohexylamino)propane-1,2-diol Chemical compound OCC(O)CNC1CCCCC1 YDVGXVAWWFKAKA-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
UFACSEIVZXTBMF-UHFFFAOYSA-N 3-methyl-8-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1C(C)(O)CC2CCC1N2C1=NC=NC2=C1C=CN2 UFACSEIVZXTBMF-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
DYQVRDISZFVXHV-UHFFFAOYSA-N 4-(methylazaniumyl)cyclohexane-1-carboxylate Chemical compound CNC1CCC(C(O)=O)CC1 DYQVRDISZFVXHV-UHFFFAOYSA-N 0.000 description 1
CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 1
FTYXRILYMGQZIW-UHFFFAOYSA-N 4-chloro-5-nitro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C([N+](=O)[O-])=CNC2=N1 FTYXRILYMGQZIW-UHFFFAOYSA-N 0.000 description 1
KAUCHHKKEDFVMC-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidin-5-amine Chemical compound N1C=NC(Cl)=C2C(N)=CN=C21 KAUCHHKKEDFVMC-UHFFFAOYSA-N 0.000 description 1
NSUSWVBAKBSLBP-UHFFFAOYSA-N 4-cyclohexyloxy-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CCCCC1OC1=NC=NC2=C1C=CN2 NSUSWVBAKBSLBP-UHFFFAOYSA-N 0.000 description 1
FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
OKIASFSQEMDXBB-UHFFFAOYSA-N 5-chloro-n-cycloheptyl-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=C(Cl)C=2C=1N(C)C1CCCCCC1 OKIASFSQEMDXBB-UHFFFAOYSA-N 0.000 description 1
PRRYQINUAIQTFJ-UHFFFAOYSA-N 5-phenyl-4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CCCCN1C1=NC=NC2=C1C(C=1C=CC=CC=1)=CN2 PRRYQINUAIQTFJ-UHFFFAOYSA-N 0.000 description 1
CDJBDMNUBKPNQF-UHFFFAOYSA-N 7-(benzenesulfonyl)-4-chloro-5-iodopyrrolo[2,3-d]pyrimidine Chemical compound C1=C(I)C=2C(Cl)=NC=NC=2N1S(=O)(=O)C1=CC=CC=C1 CDJBDMNUBKPNQF-UHFFFAOYSA-N 0.000 description 1
RBTRNZJHABCLOO-UHFFFAOYSA-N 7-(benzenesulfonyl)-4-chloro-6-phenylpyrrolo[2,3-d]pyrimidine Chemical compound C=1C=2C(Cl)=NC=NC=2N(S(=O)(=O)C=2C=CC=CC=2)C=1C1=CC=CC=C1 RBTRNZJHABCLOO-UHFFFAOYSA-N 0.000 description 1
HPWMGRLPNPQCQX-UHFFFAOYSA-N 7-(benzenesulfonyl)-4-chloropyrrolo[2,3-d]pyrimidine Chemical compound C1=CC=2C(Cl)=NC=NC=2N1S(=O)(=O)C1=CC=CC=C1 HPWMGRLPNPQCQX-UHFFFAOYSA-N 0.000 description 1
KMWWCJXJJNHTQL-UHFFFAOYSA-N 7-benzyl-4-chloropyrrolo[2,3-d]pyrimidine Chemical compound C1=CC=2C(Cl)=NC=NC=2N1CC1=CC=CC=C1 KMWWCJXJJNHTQL-UHFFFAOYSA-N 0.000 description 1
BKTPINBCXUXACV-UHFFFAOYSA-N 7-benzyl-4-cyclohexyloxypyrrolo[2,3-d]pyrimidine Chemical compound C1=CC2=C(OC3CCCCC3)N=CN=C2N1CC1=CC=CC=C1 BKTPINBCXUXACV-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101100244083 Arabidopsis thaliana PKL gene Proteins 0.000 description 1
MMCURKVELNAMRD-UHFFFAOYSA-N C1C(C2CCCC22)CC2C1N(C)C1=NC=NC2=C1C=CN2 Chemical compound C1C(C2CCCC22)CC2C1N(C)C1=NC=NC2=C1C=CN2 MMCURKVELNAMRD-UHFFFAOYSA-N 0.000 description 1
125000000172 C5-C10 aryl group Chemical group 0.000 description 1
NBIUMGHLBQFXSM-UHFFFAOYSA-N CC(C(O)C1=CC=CC=C1)C.CN(C(C(O)C1=CC=CC=C1)C)C=1C2=C(N=CN1)NC=C2 Chemical compound CC(C(O)C1=CC=CC=C1)C.CN(C(C(O)C1=CC=CC=C1)C)C=1C2=C(N=CN1)NC=C2 NBIUMGHLBQFXSM-UHFFFAOYSA-N 0.000 description 1
PSJQHQDFJZKGCA-UHFFFAOYSA-N CC1(CC(CCC1)CN)C.CC1(CC(CCC1)N(C=1C2=C(N=CN1)NC=C2)C)C Chemical compound CC1(CC(CCC1)CN)C.CC1(CC(CCC1)N(C=1C2=C(N=CN1)NC=C2)C)C PSJQHQDFJZKGCA-UHFFFAOYSA-N 0.000 description 1
ZNVWUMODJSIGEE-UHFFFAOYSA-N CC1CC(CC(C1)C)CN.CC1CC(CC(C1)C)N(C=1C2=C(N=CN1)NC=C2)C Chemical compound CC1CC(CC(C1)C)CN.CC1CC(CC(C1)C)N(C=1C2=C(N=CN1)NC=C2)C ZNVWUMODJSIGEE-UHFFFAOYSA-N 0.000 description 1
TYNXQMIMJVWKOL-UHFFFAOYSA-N CC1CC(CCC1C)CN.CC1CC(CCC1C)N(C=1C2=C(N=CN1)NC=C2)C Chemical compound CC1CC(CCC1C)CN.CC1CC(CCC1C)N(C=1C2=C(N=CN1)NC=C2)C TYNXQMIMJVWKOL-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000792859 Enema Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
108090000172 Interleukin-15 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
PYFSCIWXNSXGNS-UHFFFAOYSA-N N-methylbutan-2-amine Chemical compound CCC(C)NC PYFSCIWXNSXGNS-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
XGROBBDTGPGHRY-UHFFFAOYSA-N NCC1CCc2cc(Cl)ccc12.CN(C1CCc2cc(Cl)ccc12)c1ncnc2[nH]ccc12 Chemical compound NCC1CCc2cc(Cl)ccc12.CN(C1CCc2cc(Cl)ccc12)c1ncnc2[nH]ccc12 XGROBBDTGPGHRY-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
241001401345 Piperia Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004146 Propane-1,2-diol Substances 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
101150085390 RPM1 gene Proteins 0.000 description 1
108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000005256 alkoxyacyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
150000001543 aryl boronic acids Chemical class 0.000 description 1
150000001503 aryl iodides Chemical class 0.000 description 1
238000013096 assay test Methods 0.000 description 1
125000004069 aziridinyl group Chemical group 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
JEPPYVOSGKWVSJ-UHFFFAOYSA-N bicyclo[2.2.1]heptan-3-amine Chemical compound C1CC2C(N)CC1C2 JEPPYVOSGKWVSJ-UHFFFAOYSA-N 0.000 description 1
LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
LQNHRNOPWKZUSN-UHFFFAOYSA-N cyclobutylmethanamine Chemical compound NCC1CCC1 LQNHRNOPWKZUSN-UHFFFAOYSA-N 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
CMKBCTPCXZNQKX-UHFFFAOYSA-N cyclohexanethiol Chemical compound SC1CCCCC1 CMKBCTPCXZNQKX-UHFFFAOYSA-N 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
UBLYEVLMRSPMOG-UHFFFAOYSA-N cyclopentylmethanamine Chemical compound NCC1CCCC1 UBLYEVLMRSPMOG-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
229960004132 diethyl ether Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
BZWWGVZIZQCGKE-UHFFFAOYSA-N ethyl 4-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexane-1-carboxylate Chemical compound C1CC(C(=O)OCC)CCC1N(C)C1=NC=NC2=C1C=CN2 BZWWGVZIZQCGKE-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
102000049912 human JAK3 Human genes 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
QQLZCTOIJOVFOB-UHFFFAOYSA-N n'-cyclohexyl-n,n-dimethyl-n'-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)propane-1,3-diamine Chemical compound N=1C=NC=2NC=CC=2C=1N(CCCN(C)C)C1CCCCC1 QQLZCTOIJOVFOB-UHFFFAOYSA-N 0.000 description 1
YJALUEIBZWBMAQ-UHFFFAOYSA-N n,2,2,5,5-pentamethylcyclohexan-1-amine Chemical compound CNC1CC(C)(C)CCC1(C)C YJALUEIBZWBMAQ-UHFFFAOYSA-N 0.000 description 1
DWROGSGKFAWAEJ-UHFFFAOYSA-N n,2,5,5-tetramethylcyclohexan-1-amine Chemical compound CNC1CC(C)(C)CCC1C DWROGSGKFAWAEJ-UHFFFAOYSA-N 0.000 description 1
HMDSHIZGTPRJHT-UHFFFAOYSA-N n,2-dimethylcyclohexan-1-amine Chemical compound CNC1CCCCC1C HMDSHIZGTPRJHT-UHFFFAOYSA-N 0.000 description 1
DBIKWHSBKVRPBS-UHFFFAOYSA-N n,3,3,5-tetramethylcyclohexan-1-amine Chemical compound CNC1CC(C)CC(C)(C)C1 DBIKWHSBKVRPBS-UHFFFAOYSA-N 0.000 description 1
KYMXBBBWJVWQSX-UHFFFAOYSA-N n,3-dimethylcyclopentan-1-amine Chemical compound CNC1CCC(C)C1 KYMXBBBWJVWQSX-UHFFFAOYSA-N 0.000 description 1
VYPUNQUBISHTFD-UHFFFAOYSA-N n-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-yl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CCC2CCCCC2C1N(C)C1=NC=NC2=C1C=CN2 VYPUNQUBISHTFD-UHFFFAOYSA-N 0.000 description 1
SVEYUCAAQGSLKP-UHFFFAOYSA-N n-(2,4-dimethylcyclohexyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1CC(C)CCC1N(C)C1=NC=NC2=C1C=CN2 SVEYUCAAQGSLKP-UHFFFAOYSA-N 0.000 description 1
SFYRXYZOYTZGHI-UHFFFAOYSA-N n-(2,5-dimethylcyclohexyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(C)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 SFYRXYZOYTZGHI-UHFFFAOYSA-N 0.000 description 1
PBBBLFGDZLEXBK-UHFFFAOYSA-N n-(2-methoxyethyl)cycloheptanamine Chemical compound COCCNC1CCCCCC1 PBBBLFGDZLEXBK-UHFFFAOYSA-N 0.000 description 1
BNBQYPFUNLPVFT-UHFFFAOYSA-N n-(2-methoxyethyl)cyclooctanamine Chemical compound COCCNC1CCCCCCC1 BNBQYPFUNLPVFT-UHFFFAOYSA-N 0.000 description 1
QCRDIQHOUQENDU-UHFFFAOYSA-N n-(3,5-dimethylcyclohexyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(C)CC(C)CC1N(C)C1=NC=NC2=C1C=CN2 QCRDIQHOUQENDU-UHFFFAOYSA-N 0.000 description 1
IYZZATYWTGOKGJ-UHFFFAOYSA-N n-(3-bicyclo[2.2.1]heptanyl)-5-phenyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CC2CC1CC2NC(C1=2)=NC=NC=2NC=C1C1=CC=CC=C1 IYZZATYWTGOKGJ-UHFFFAOYSA-N 0.000 description 1
KIKDAHWCFFYGLP-UHFFFAOYSA-N n-(3-ethylcyclopentyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(CC)CCC1N(C)C1=NC=NC2=C1C=CN2 KIKDAHWCFFYGLP-UHFFFAOYSA-N 0.000 description 1
ZIBKSFRQHFJFRW-UHFFFAOYSA-N n-(9-bicyclo[3.3.1]nonanyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CCC2CCCC1C2N(C)C1=NC=NC2=C1C=CN2 ZIBKSFRQHFJFRW-UHFFFAOYSA-N 0.000 description 1
GBUIDKKADOXANX-UHFFFAOYSA-N n-[1-(4-chlorophenoxy)propan-2-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C(C)COC1=CC=C(Cl)C=C1 GBUIDKKADOXANX-UHFFFAOYSA-N 0.000 description 1
OXYWICKYMJDUNG-UHFFFAOYSA-N n-[2-(cyclohexylamino)ethyl]acetamide Chemical compound CC(=O)NCCNC1CCCCC1 OXYWICKYMJDUNG-UHFFFAOYSA-N 0.000 description 1
ZZGMVHYLPMNQPM-UHFFFAOYSA-N n-cyclobutyl-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C1CCC1 ZZGMVHYLPMNQPM-UHFFFAOYSA-N 0.000 description 1
JCRZZQAGLNAMDS-UHFFFAOYSA-N n-cycloheptyl-n-(2-methoxyethyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(CCOC)C1CCCCCC1 JCRZZQAGLNAMDS-UHFFFAOYSA-N 0.000 description 1
HBFYEQMGGHBNJA-UHFFFAOYSA-N n-cycloheptyl-n-cyclopropyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CC1N(C=1C=2C=CNC=2N=CN=1)C1CCCCCC1 HBFYEQMGGHBNJA-UHFFFAOYSA-N 0.000 description 1
ZNQMUJSFCXAIQK-UHFFFAOYSA-N n-cycloheptyl-n-ethyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(CC)C1CCCCCC1 ZNQMUJSFCXAIQK-UHFFFAOYSA-N 0.000 description 1
ZFIGXIDXDAXIOH-UHFFFAOYSA-N n-cyclohexyl-5-(4-fluorophenyl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=C(C=3C=CC(F)=CC=3)C=2C=1N(C)C1CCCCC1 ZFIGXIDXDAXIOH-UHFFFAOYSA-N 0.000 description 1
RWPXVMZAMHCFBI-UHFFFAOYSA-N n-cyclohexyl-6-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=CN=C2NC(C)=CC2=C1NC1CCCCC1 RWPXVMZAMHCFBI-UHFFFAOYSA-N 0.000 description 1
XUOJALWUMHTTIM-UHFFFAOYSA-N n-cyclohexyl-n,6-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC(C)=CC=2C=1N(C)C1CCCCC1 XUOJALWUMHTTIM-UHFFFAOYSA-N 0.000 description 1
KNGMHNAKUXKPJT-UHFFFAOYSA-N n-cyclohexyl-n-methyl-5-phenyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=C(C=3C=CC=CC=3)C=2C=1N(C)C1CCCCC1 KNGMHNAKUXKPJT-UHFFFAOYSA-N 0.000 description 1
UCOZXARHJOLLFO-UHFFFAOYSA-N n-cyclohexyl-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C1CCCCC1 UCOZXARHJOLLFO-UHFFFAOYSA-N 0.000 description 1
IQELVAHZGXJFFN-UHFFFAOYSA-N n-cyclopentyl-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C1CCCC1 IQELVAHZGXJFFN-UHFFFAOYSA-N 0.000 description 1
UEKBSARWTFIGRW-UHFFFAOYSA-N n-methyl-2-propylcyclohexan-1-amine Chemical compound CCCC1CCCCC1NC UEKBSARWTFIGRW-UHFFFAOYSA-N 0.000 description 1
WFYLYILBSKTJFH-UHFFFAOYSA-N n-methyl-n-(1,2,3,4-tetrahydronaphthalen-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CC2=CC=CC=C2CC1N(C)C1=NC=NC2=C1C=CN2 WFYLYILBSKTJFH-UHFFFAOYSA-N 0.000 description 1
IJBXNTHEYZORLV-UHFFFAOYSA-N n-methyl-n-(2,2,5,5-tetramethylcyclohexyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C1CC(C)(C)CCC1(C)C IJBXNTHEYZORLV-UHFFFAOYSA-N 0.000 description 1
BOOTXBLKDYKDTG-UHFFFAOYSA-N n-methyl-n-(2-methylcyclohexyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1CCCCC1N(C)C1=NC=NC2=C1C=CN2 BOOTXBLKDYKDTG-UHFFFAOYSA-N 0.000 description 1
CHECMABHXODVTG-UHFFFAOYSA-N n-methyl-n-(2-propylcyclohexyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CCCC1CCCCC1N(C)C1=NC=NC2=C1C=CN2 CHECMABHXODVTG-UHFFFAOYSA-N 0.000 description 1
HKGCTNOMFGIQPR-UHFFFAOYSA-N n-methyl-n-(3,3,5-trimethylcyclohexyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(C)(C)CC(C)CC1N(C)C1=NC=NC2=C1C=CN2 HKGCTNOMFGIQPR-UHFFFAOYSA-N 0.000 description 1
VPKQGLHLFZPKJP-UHFFFAOYSA-N n-methyl-n-(4-methylcyclohexyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CC(C)CCC1N(C)C1=NC=NC2=C1C=CN2 VPKQGLHLFZPKJP-UHFFFAOYSA-N 0.000 description 1
RNIJSZGJNGTOTB-UHFFFAOYSA-N n-methylbicyclo[2.2.1]heptan-3-amine Chemical compound C1CC2C(NC)CC1C2 RNIJSZGJNGTOTB-UHFFFAOYSA-N 0.000 description 1
QTHHPUFBKSSQPA-UHFFFAOYSA-N n-methylbicyclo[3.3.1]nonan-9-amine Chemical compound C1CCC2CCCC1C2NC QTHHPUFBKSSQPA-UHFFFAOYSA-N 0.000 description 1
CTSIKBGUCQWRIM-UHFFFAOYSA-N n-prop-2-enylcyclopentanamine Chemical compound C=CCNC1CCCC1 CTSIKBGUCQWRIM-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
125000000466 oxiranyl group Chemical group 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940093932 potassium hydroxide Drugs 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
AHRQYOSAXZQCIG-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=C=NC=N[CH]1 AHRQYOSAXZQCIG-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229960001866 silicon dioxide Drugs 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
DDAXOMGIYZMQKN-UHFFFAOYSA-N t6239674 Chemical compound C12CCCC2C2CC(NC)C1C2 DDAXOMGIYZMQKN-UHFFFAOYSA-N 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
ICMSIBMHHMSMHL-UHFFFAOYSA-N tert-butyl n-[2-[cycloheptyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]carbamate Chemical compound N=1C=NC=2NC=CC=2C=1N(CCNC(=O)OC(C)(C)C)C1CCCCCC1 ICMSIBMHHMSMHL-UHFFFAOYSA-N 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000005306 thianaphthenyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
FWSPXZXVNVQHIF-UHFFFAOYSA-N triethyl(ethynyl)silane Chemical group CC[Si](CC)(CC)C#C FWSPXZXVNVQHIF-UHFFFAOYSA-N 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Natural products NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200000349A 1998-06-19 1999-06-14 PyrroloÄ2,3-düpyrimidine compounds. OA11572A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8986698P	1998-06-19	1998-06-19
US10478798P	1998-10-19	1998-10-19

Publications (1)

Publication Number	Publication Date
OA11572A true OA11572A (en)	2004-07-01

Family

ID=26781018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000349A OA11572A (en)	1998-06-19	1999-06-14	PyrroloÄ2,3-düpyrimidine compounds.

Country Status (40)

Country	Link
US (3)	US6610847B2 (de)
EP (1)	EP1087970B1 (de)
JP (3)	JP4666762B2 (de)
KR (1)	KR100415791B1 (de)
CN (1)	CN1128800C (de)
AP (1)	AP1021A (de)
AR (1)	AR016499A1 (de)
AT (1)	ATE265458T1 (de)
AU (1)	AU3951899A (de)
BG (1)	BG65119B1 (de)
BR (1)	BR9911365A (de)
CA (1)	CA2335492C (de)
CZ (1)	CZ20004727A3 (de)
DE (1)	DE69916833T2 (de)
DK (1)	DK1087970T3 (de)
EA (1)	EA005852B1 (de)
ES (1)	ES2219018T3 (de)
FR (1)	FR14C0019I2 (de)
GE (1)	GEP20074227B (de)
GT (1)	GT199900090A (de)
HR (1)	HRP20000885B1 (de)
HU (1)	HUP0102574A3 (de)
ID (1)	ID26698A (de)
IL (1)	IL139586A0 (de)
MA (1)	MA26654A1 (de)
MY (1)	MY125916A (de)
NO (2)	NO318784B1 (de)
NZ (1)	NZ518444A (de)
OA (1)	OA11572A (de)
PA (1)	PA8476001A1 (de)
PE (1)	PE20000698A1 (de)
PL (1)	PL198640B1 (de)
PT (1)	PT1087970E (de)
RS (1)	RS50087B (de)
SA (1)	SA99200283B1 (de)
SK (1)	SK286640B6 (de)
TN (1)	TNSN99126A1 (de)
TR (1)	TR200003719T2 (de)
TW (1)	TW505646B (de)
WO (1)	WO1999065908A1 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3951899A (en) *	1998-06-19	2000-01-05	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
OA12118A (en)	1999-12-10	2006-05-04	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds.
OA12292A (en) *	2000-06-26	2003-11-11	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
PL359920A1 (en)	2000-09-20	2004-09-06	Merck Patent Gmbh	4-amino-quinazolines
US7067550B2 (en) *	2000-11-03	2006-06-27	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's Disease
DE10063294A1 (de) *	2000-12-19	2002-07-04	Aventis Pharma Gmbh	Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO2002060492A1 (en) *	2001-01-30	2002-08-08	Cytopia Pty Ltd	Methods of inhibiting kinases
SK11322003A3 (en)	2001-02-12	2004-10-05	Hoffmann La Roche	6-Substituted pyrido-pyrimidines
US7301023B2 (en) *	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
GB0115393D0 (en) *	2001-06-23	2001-08-15	Aventis Pharma Ltd	Chemical compounds
DE60227709D1 (de) *	2001-06-29	2008-08-28	Ab Science	Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
ES2274993T3 (es)	2001-06-29	2007-06-01	Ab Science	Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
PT1401416E (pt) *	2001-06-29	2007-02-28	Ab Science	Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
ATE330608T1 (de)	2001-06-29	2006-07-15	Ab Science	Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
WO2003003006A2 (en)	2001-06-29	2003-01-09	Ab Science	New potent, selective and non toxic c-kit inhibitors
GB0119249D0 (en)	2001-08-07	2001-10-03	Novartis Ag	Organic compounds
US7323469B2 (en)	2001-08-07	2008-01-29	Novartis Ag	7H-pyrrolo[2,3-d]pyrimidine derivatives
US7829566B2 (en)	2001-09-17	2010-11-09	Werner Mederski	4-amino-quinazolines
PY0228255A (es)	2001-12-06	2004-06-01	Pfizer Prod Inc	Compuestos cristalinos novedosos
EP1465900B1 (de) *	2002-01-10	2008-05-14	Bayer HealthCare AG	Rho-kinase inhibitoren
CA2473910C (en)	2002-01-23	2011-03-15	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives as rho-kinase inhibitors
MXPA04007191A (es)	2002-01-23	2005-03-31	Bayer Pharmaceuticals Corp	Derivados de pirimidina como inhibidores de rho-quinasa.
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
EP1388541A1 (de) *	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazine als Kinasehemmer
WO2004047843A1 (en) *	2002-11-26	2004-06-10	Pfizer Products Inc.	Method of treatment of transplant rejection
US7169918B2 (en) *	2003-10-27	2007-01-30	Genelabs Technologies, Inc.	Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
CA2545192A1 (en) *	2003-11-25	2005-06-09	Pfizer Products Inc.	Method of treatment of atherosclerosis
WO2005095357A2 (en) *	2004-03-30	2005-10-13	Taisho Pharmaceutical Co., Ltd.	Pyrimidine derivatives and methods of treatment related to the use thereof
EP1768662A2 (de)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Immunstimulatoren kleiner moleküle und assays für deren nachweis
MXPA06015237A (es)	2004-06-29	2007-12-10	Amgen Inc	Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
MX2007001399A (es)	2004-08-02	2007-04-18	Osi Pharm Inc	Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7423043B2 (en) *	2005-02-18	2008-09-09	Lexicon Pharmaceuticals, Inc.	4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
WO2006124462A2 (en)	2005-05-13	2006-11-23	Irm, Llc	Compounds and compositions as protein kinase inhibitors
CN102127078A (zh)	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
JP5071374B2 (ja)	2005-07-14	2012-11-14	アステラス製薬株式会社	ヘテロ環ヤヌスキナーゼ３阻害剤
WO2007038215A1 (en)	2005-09-22	2007-04-05	Incyte Corporation	Tetracyclic inhibitors of janus kinases
CN101801971A (zh)	2005-09-30	2010-08-11	沃泰克斯药物股份有限公司	可用作janus激酶抑制剂的脱氮嘌呤
HUE028588T2 (hu)	2005-12-13	2016-12-28	Incyte Holdings Corp	Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
US20100273776A1 (en) *	2006-03-29	2010-10-28	FOLDRx PHARMACEUTICALS, INC	Inhibition of alpha-synuclein toxicity
WO2007125321A2 (en)	2006-04-25	2007-11-08	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
ES2415863T3 (es)	2006-12-22	2013-07-29	Incyte Corporation	Heterociclos sustituidos como inhibidores de Janus Quinasas
US20100105661A1 (en)	2007-01-12	2010-04-29	Astellas Pharma Inc.	Condensed pyridine compound
EP2142550A1 (de) *	2007-04-02	2010-01-13	Palau Pharma, S.A.	Pyrrolopyrimidinderivate als jak3-inhibitoren
EP2740731B1 (de)	2007-06-13	2016-03-23	Incyte Holdings Corporation	Kristalline Salze des Janus-Kinasehemmers (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-YL)-1H-pyrazol-1-YL)-3-cyclopentylpropanenitril
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
DE102007027800A1 (de)	2007-06-16	2008-12-18	Bayer Healthcare Ag	Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
MX2010005116A (es) *	2007-11-10	2010-09-09	Landmark Graphics Corp	Sistemas y metodos para automatizacion, adaptacion e integracion del flujo de trabajo.
BRPI0819453A2 (pt) *	2007-11-28	2014-10-07	Dana Farber Cancer Inst Inc	Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
UY31631A1 (es)	2008-02-06	2009-09-30		Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
RU2503676C2 (ru) *	2008-02-25	2014-01-10	Ф.Хоффманн-Ля Рош Аг	Пирролопиразиновые ингибиторы киназы
MY165582A (en)	2008-03-11	2018-04-05	Incyte Holdings Corp	Azetidine and cyclobutane derivatives as jak inhibitors
WO2009115084A2 (de) *	2008-03-20	2009-09-24	Schebo Biotech Ag	Neue pyrrolopyrimidin-derivate und deren verwendungen
CA2728559A1 (en) *	2008-07-03	2010-01-07	Exelixis Inc.	Cdk modulators
RU2011105768A (ru) *	2008-08-01	2012-09-10	Биокрист Фармасьютикалз, Инк. (Us)	Производные пиперидина в качестве ингибиторов jakз
RS53382B (sr)	2008-08-20	2014-10-31	Zoetis Llc	Jedinjenja pirol [2,3-d]pirimidina
US8385364B2 (en) *	2008-09-24	2013-02-26	Nec Laboratories America, Inc.	Distributed message-passing based resource allocation in wireless systems
CA2759026C (en)	2009-04-20	2019-01-15	Auspex Pharmaceuticals, Inc.	Piperidine inhibitors of janus kinase 3
BRPI1012108B8 (pt)	2009-05-22	2021-05-25	Incyte Corp	composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en)	2009-05-22	2014-01-31	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5690823B2 (ja)	2009-07-08	2015-03-25	レオファーマアクティーゼルスカブ	Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
TWI466885B (zh) *	2009-07-31	2015-01-01	Japan Tobacco Inc	含氮螺環化合物及其醫藥用途
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru)	2009-10-09	2015-06-30	Инсайт Корпорейшн	ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
AU2010308028A1 (en)	2009-10-15	2012-04-19	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
CA2782720A1 (en) *	2009-12-18	2011-06-23	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds
AU2011213198B2 (en)	2010-02-05	2014-04-24	Zoetis Llc	Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
EP2360158A1 (de) *	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazolderivate als JAK-Inhibitoren
CA2792508C (en)	2010-03-10	2018-01-16	Incyte Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9586961B2 (en) *	2010-07-09	2017-03-07	Leo Pharma A/S	Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
ES2536415T3 (es)	2010-11-19	2015-05-25	Incyte Corporation	Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN103298817A (zh) *	2011-01-07	2013-09-11	利奥制药有限公司	作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
WO2012112847A1 (en)	2011-02-18	2012-08-23	Novartis Pharma Ag	mTOR/JAK INHIBITOR COMBINATION THERAPY
AU2012232658B2 (en)	2011-03-22	2016-06-09	Advinus Therapeutics Limited	Substituted fused tricyclic compounds, compositions and medicinal applications thereof
MX2013013331A (es) *	2011-05-17	2014-10-17	Principia Biopharma Inc	Derivados de azaindol como inhibidores de tirosina-cinasas.
US8691807B2 (en)	2011-06-20	2014-04-08	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013023119A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
US9089574B2 (en) *	2011-11-30	2015-07-28	Emory University	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
JP6075736B2 (ja) *	2011-12-21	2017-02-08	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104470931B (zh)	2012-05-21	2016-10-26	拜耳医药股份有限公司	取代的苯并噻吩并嘧啶
EA025186B1 (ru)	2012-06-29	2016-11-30	Пфайзер Инк.	НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
CN104619693B (zh) *	2012-07-17	2019-08-13	葛兰素史克知识产权第二有限公司	作为选择性雄激素受体调节剂的吲哚腈类
PT2874630T (pt) *	2012-07-20	2019-01-31	Zoetis Services Llc	Regime de dosagem para inibidores de janus quinase (jak)
TW201412740A (zh) *	2012-09-20	2014-04-01	Bayer Pharma AG	經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014045305A1 (en)	2012-09-21	2014-03-27	Advinus Therapeutics Limited	Substituted fused tricyclic compounds, compositions and medicinal applications thereof
CN102936251A (zh) *	2012-11-05	2013-02-20	上海毕得医药科技有限公司	一种吡咯并[2,3-d]嘧啶衍生物的制备方法
KR102242077B1 (ko)	2012-11-15	2021-04-20	인사이트 홀딩스 코포레이션	룩솔리티니브의 서방성 제형
KR101683061B1 (ko) *	2013-02-07	2016-12-07	한국과학기술연구원	ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
EA027879B1 (ru) *	2013-02-22	2017-09-29	Пфайзер Инк.	ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EP3489239B1 (de)	2013-03-06	2021-09-15	Incyte Holdings Corporation	Verfahren und zwischenprodukte zur herstellung eines jak-hemmers
WO2014139388A1 (en) *	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
MX376856B (es)	2013-08-07	2025-03-07	Incyte Holdings Corp	Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
LT3077395T (lt)	2013-12-05	2018-02-12	Pfizer Inc.	Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
EP3083618B1 (de)	2013-12-17	2018-02-21	Pfizer Inc	Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CA2984183C (en)	2015-05-01	2021-11-09	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
DK3305788T3 (da) *	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus-kinase-hæmmer
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
RU2722149C1 (ru)	2015-09-14	2020-05-27	Пфайзер Инк.	Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
CN106831779B (zh) *	2015-11-28	2019-07-19	南昌弘益药业有限公司	一类jak激酶抑制剂的新化合物
RU2699034C1 (ru)	2016-02-16	2019-09-03	ЗОИТИС СЕРВИСЕЗ ЭлЭлСи	Способ получения соединений 7H-пирроло[2,3-d]пиримидина
CN107098908B (zh) *	2016-02-23	2021-01-08	欣凯医药科技(上海)有限公司	一种吡咯并嘧啶类化合物的制备方法和应用
AU2017376398B2 (en)	2016-12-14	2021-07-15	Intervet International B.V.	Aminopyrazoles as selective janus kinase inhibitors
JP6944496B2 (ja)	2018-10-22	2021-10-06	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
JP2022506682A (ja) *	2018-11-05	2022-01-17	アビスタファーマソリューションズ，インコーポレーテッド	化合物
WO2020142557A1 (en)	2018-12-31	2020-07-09	Biomea Fusion, Llc	Irreversible inhibitors of menin-mll interaction
TW202043205A (zh) *	2018-12-31	2020-12-01	美商拜歐米富士恩有限公司	Menin-mll相互作用之抑制劑
NL2022471B1 (en)	2019-01-29	2020-08-18	Vationpharma B V	Solid state forms of oclacitinib
EP3946606B1 (de)	2019-03-27	2025-01-01	Insilico Medicine IP Limited	Bicyclische jak-inhibitoren und verwendungen davon
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022133420A1 (en)	2020-12-18	2022-06-23	Boehringer Ingelheim Animal Health USA Inc.	Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
JP7891524B2 (ja)	2021-08-11	2026-07-16	バイオメアフュージョン，インコーポレイテッド	真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤
MX2024002189A (es)	2021-08-20	2024-06-11	Biomea Fusion Inc	Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
WO2023029943A1 (zh) *	2021-09-03	2023-03-09	星药科技(北京)有限公司	一种芳杂环化合物及其制备方法和用途
US20250051337A1 (en) *	2021-09-28	2025-02-13	Sanford Burnham Prebys Medical Discovery Institute	Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023118555A1 (en)	2021-12-24	2023-06-29	Intervet International B.V.	Use of aminopyrazole compounds
GB202215132D0 (en) *	2022-10-13	2022-11-30	Norwegian Univ Sci & Tech Ntnu	Compound
GB202215117D0 (en) *	2022-10-13	2022-11-30	Norwegian Univ Sci & Tech Ntnu	Compound
WO2024155719A1 (en)	2023-01-18	2024-07-25	Biomea Fusion, Inc.	Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3037980A (en)	1955-08-18	1962-06-05	Burroughs Wellcome Co	Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en)	1958-03-13	1963-01-09	Wellcome Found	Pyrrolo[2,3-d]pyrimidine derivatives
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5389509A (en)	1993-10-04	1995-02-14	Eastman Kodak Company	Ultrathin high chloride tabular grain emulsions
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (es) *	1994-05-03	1998-01-16	Ciba Geigy Ag	Derivados de pirrolopirimidilo con efecto antiproliferante.
CA2223081C (en) *	1995-06-07	2001-03-06	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
MX9800136A (es)	1995-07-05	1998-03-29	Du Pont	Pirimidinonas fungicidas.
PL188959B1 (pl) *	1995-07-06	2005-05-31	Novartis Ag	Pirolopirymidyny i sposoby ich wytwarzania
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
HUP9801177A3 (en)	1995-11-14	1998-11-30	Pharmacia & Upjohn Spa	Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them
US6140317A (en)	1996-01-23	2000-10-31	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) *	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de)	1996-03-06	1997-09-12	Novartis Ag	7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
AR007855A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
PT938486E (pt) *	1996-08-23	2008-03-27	Novartis Ag	Pirrolopirimidinas substituídas e processos para a sua preparação
IL129825A0 (en) *	1996-11-27	2000-02-29	Pfizer	Fused bicyclic pyrimidine derivatives
ES2301194T3 (es)	1997-02-05	2008-06-16	Warner-Lambert Company Llc	Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
WO1998043087A1 (en)	1997-03-24	1998-10-01	Pharmacia & Upjohn Company	Method for identifying inhibitors of jak2/cytokine receptor binding
US6080847A (en) *	1997-12-04	2000-06-27	Incyte Pharmaceuticals, Inc.	Proteins associated with cell proliferation
US6310063B1 (en)	1998-04-02	2001-10-30	Neurogen Corporation	Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
HUP0102793A3 (en)	1998-05-28	2002-07-29	Parker Hughes Inst St Paul	Quinazolines for treating brain tumor and medicaments containing them
AU3951899A (en) *	1998-06-19	2000-01-05	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds
JP2004504259A (ja)	1998-06-30	2004-02-12	パーカー　ヒューズ　インスティテュート	Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
AU5682799A (en)	1998-08-21	2000-03-14	Parker Hughes Institute	Quinazoline derivatives
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
OA12118A (en) *	1999-12-10	2006-05-04	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds.
OA12292A (en) *	2000-06-26	2003-11-11	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
AU2009100870A4 (en)	2008-10-01	2009-10-22	Rock Tone Enterprise Co., Ltd.	Drive mechanism for dehydrator
TWM358618U (en)	2008-12-26	2009-06-11	Rock Tone Entpr Co Ltd	Combination structure of mop holder and cleaning body

1999
- 1999-06-14 AU AU39518/99A patent/AU3951899A/en not_active Abandoned
- 1999-06-14 BR BR9911365-1A patent/BR9911365A/pt not_active Application Discontinuation
- 1999-06-14 ES ES99922454T patent/ES2219018T3/es not_active Expired - Lifetime
- 1999-06-14 TR TR2000/03719T patent/TR200003719T2/xx unknown
- 1999-06-14 DE DE69916833T patent/DE69916833T2/de not_active Expired - Lifetime
- 1999-06-14 WO PCT/IB1999/001100 patent/WO1999065908A1/en not_active Ceased
- 1999-06-14 EP EP99922454A patent/EP1087970B1/de not_active Expired - Lifetime
- 1999-06-14 KR KR10-2000-7014402A patent/KR100415791B1/ko not_active Expired - Lifetime
- 1999-06-14 OA OA1200000349A patent/OA11572A/en unknown
- 1999-06-14 PT PT99922454T patent/PT1087970E/pt unknown
- 1999-06-14 CZ CZ20004727A patent/CZ20004727A3/cs unknown
- 1999-06-14 JP JP2000554733A patent/JP4666762B2/ja not_active Expired - Lifetime
- 1999-06-14 DK DK99922454T patent/DK1087970T3/da active
- 1999-06-14 ID IDW20002644A patent/ID26698A/id unknown
- 1999-06-14 RS YUP-785/00A patent/RS50087B/sr unknown
- 1999-06-14 IL IL13958699A patent/IL139586A0/xx active Protection Beyond IP Right Term
- 1999-06-14 CA CA002335492A patent/CA2335492C/en not_active Expired - Lifetime
- 1999-06-14 PL PL345123A patent/PL198640B1/pl unknown
- 1999-06-14 HU HU0102574A patent/HUP0102574A3/hu unknown
- 1999-06-14 CN CN99807521A patent/CN1128800C/zh not_active Ceased
- 1999-06-14 SK SK1898-2000A patent/SK286640B6/sk not_active IP Right Cessation
- 1999-06-14 HR HR20000885A patent/HRP20000885B1/xx not_active IP Right Cessation
- 1999-06-14 EA EA200001203A patent/EA005852B1/ru not_active IP Right Cessation
- 1999-06-14 AT AT99922454T patent/ATE265458T1/de not_active IP Right Cessation
- 1999-06-14 TW TW088109926A patent/TW505646B/zh active
- 1999-06-16 MA MA25630A patent/MA26654A1/fr unknown
- 1999-06-16 PA PA19998476001A patent/PA8476001A1/es unknown
- 1999-06-16 TN TNTNSN99126A patent/TNSN99126A1/fr unknown
- 1999-06-16 PE PE1999000531A patent/PE20000698A1/es not_active Application Discontinuation
- 1999-06-17 MY MYPI99002502A patent/MY125916A/en unknown
- 1999-06-17 AP APAP/P/1999/001584A patent/AP1021A/en active
- 1999-06-17 AR ARP990102916A patent/AR016499A1/es active IP Right Grant
- 1999-06-18 GT GT199900090A patent/GT199900090A/es unknown
- 1999-06-28 SA SA99200283A patent/SA99200283B1/ar unknown
2000
- 2000-11-08 NZ NZ518444A patent/NZ518444A/en not_active Application Discontinuation
- 2000-12-18 NO NO20006453A patent/NO318784B1/no not_active IP Right Cessation
2001
- 2001-01-08 BG BG105129A patent/BG65119B1/bg unknown
- 2001-09-19 US US09/956,645 patent/US6610847B2/en not_active Expired - Lifetime
2003
- 2003-05-20 US US10/442,807 patent/US6890929B2/en not_active Expired - Lifetime
2005
- 2005-02-23 US US11/064,873 patent/US7687507B2/en not_active Expired - Fee Related
2007
- 2007-04-25 GE GEAP200710007A patent/GEP20074227B/en unknown
- 2007-08-06 JP JP2007204429A patent/JP4971068B2/ja not_active Expired - Lifetime
2011
- 2011-11-11 JP JP2011247593A patent/JP2012041365A/ja active Pending
2014
- 2014-03-07 FR FR14C0019C patent/FR14C0019I2/fr active Active
- 2014-05-13 NO NO2014012C patent/NO2014012I1/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP4666762B2 (ja)	2011-04-06
YU78500A (sh)	2003-04-30
KR100415791B1 (ko)	2004-01-24
JP2007284455A (ja)	2007-11-01
ATE265458T1 (de)	2004-05-15
BG105129A (en)	2001-11-30
TW505646B (en)	2002-10-11
MY125916A (en)	2006-08-30
JP4971068B2 (ja)	2012-07-11
TNSN99126A1 (fr)	2005-11-10
CZ20004727A3 (cs)	2002-03-13
HRP20000885A2 (en)	2001-10-31
GEP20074227B (en)	2007-10-25
KR20010053004A (ko)	2001-06-25
NO318784B1 (no)	2005-05-09
SK18982000A3 (sk)	2002-08-06
CN1305480A (zh)	2001-07-25
FR14C0019I1 (de)	2014-04-11
SA99200283B1 (ar)	2006-03-25
HRP20000885B1 (hr)	2007-03-31
HUP0102574A2 (hu)	2001-11-28
US6610847B2 (en)	2003-08-26
EP1087970B1 (de)	2004-04-28
PL345123A1 (en)	2001-12-03
CN1128800C (zh)	2003-11-26
JP2002518393A (ja)	2002-06-25
NO20006453D0 (no)	2000-12-18
FR14C0019I2 (fr)	2015-01-02
ES2219018T3 (es)	2004-11-16
NO2014012I1 (no)	2014-06-02
US6890929B2 (en)	2005-05-10
AP1021A (en)	2001-11-09
NZ518444A (en)	2004-04-30
RS50087B (sr)	2009-01-22
DE69916833T2 (de)	2005-04-14
EP1087970A1 (de)	2001-04-04
US20050171128A1 (en)	2005-08-04
US20030212273A1 (en)	2003-11-13
WO1999065908A1 (en)	1999-12-23
HUP0102574A3 (en)	2002-01-28
SK286640B6 (sk)	2009-03-05
BG65119B1 (bg)	2007-03-30
EA005852B1 (ru)	2005-06-30
US7687507B2 (en)	2010-03-30
HK1036801A1 (en)	2002-01-18
PE20000698A1 (es)	2000-08-19
GT199900090A (es)	2000-12-09
EA200001203A1 (ru)	2001-06-25
PT1087970E (pt)	2004-06-30
ID26698A (id)	2001-02-01
AP9901584A0 (en)	1999-06-30
IL139586A0 (en)	2002-02-10
CA2335492A1 (en)	1999-12-23
JP2012041365A (ja)	2012-03-01
AU3951899A (en)	2000-01-05
PL198640B1 (pl)	2008-07-31
TR200003719T2 (tr)	2001-03-21
US20020019526A1 (en)	2002-02-14
PA8476001A1 (es)	2003-09-05
NO20006453L (no)	2001-02-05
CA2335492C (en)	2005-05-17
BR9911365A (pt)	2001-03-13
MA26654A1 (fr)	2004-12-20
DK1087970T3 (da)	2004-08-02
AR016499A1 (es)	2001-07-04
DE69916833D1 (de)	2004-06-03

Publication	Publication Date	Title
AP1021A (en)	2001-11-09	Pyrrolo [2,3-d] pyrimidine compounds.
EP1666481B9 (de)	2013-05-01	3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile als Proteinkinase Inhibitor
CA2335186C (en)	2005-03-29	Pyrrolo[2,3-d]pyrimidine compounds
MXPA05005403A (es)	2005-08-03	Derivados de 3-amino-piperadina y metodos de fabricacion.
HUE030714T2 (en)	2017-05-29	Cdk inhibitors
JP2008505100A (ja)	2008-02-21	ガンマ−セクレターゼ阻害剤としての置換ｎ−アリールスルホニル複素環アミン
AU2003234874B2 (en)	2004-09-02	Pyrrolo[2,3-d]pyrimidine Compounds
MXPA00012622A (en)	2001-07-31	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
MXPA00012853A (en)	2001-09-07	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
HK1176609A1 (zh)	2013-08-02	作为血管升压素v1a受体拮抗剂的杂芳基-环己基-四氮杂苯并[e]薁